Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Cost of Revenue: 2017-2024

Historic Cost of Revenue for Puma Biotechnology (PBYI) over the last 8 years, with Dec 2024 value amounting to $64.4 million.

  • Puma Biotechnology's Cost of Revenue fell 58.16% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.0 million, marking a year-over-year decrease of 34.56%. This contributed to the annual value of $64.4 million for FY2024, which is 2.75% up from last year.
  • Latest data reveals that Puma Biotechnology reported Cost of Revenue of $64.4 million as of FY2024, which was up 2.75% from $62.7 million recorded in FY2023.
  • Puma Biotechnology's 5-year Cost of Revenue high stood at $64.4 million for FY2024, and its period low was $39.4 million during FY2020.
  • Moreover, its 3-year median value for Cost of Revenue was $62.7 million (2023), whereas its average is $60.7 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first spiked by 61.78% in 2021, then fell by 13.51% in 2022.
  • Over the past 5 years, Puma Biotechnology's Cost of Revenue (Yearly) stood at $39.4 million in 2020, then skyrocketed by 61.78% to $63.7 million in 2021, then decreased by 13.51% to $55.1 million in 2022, then increased by 13.77% to $62.7 million in 2023, then increased by 2.75% to $64.4 million in 2024.